Review of the Mechanisms of Action of Antiepileptic Drugs

CNS Drugs

Volumn 4, Issue 6, 1995, Pages 469-477

  Schachter, Steven C ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE; CARBAMAZEPINE; ETHOSUXIMIDE; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID; VIGABATRIN;

EPILEPSY; HUMAN; NERVE CELL MEMBRANE; PRIORITY JOURNAL; REVIEW; SYNAPSE;

EID: 0028807503     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/00023210-199504060-00009     Document Type: Article

References (70)

1. Sodium diphenyl hydantoinate in the treatment of convulsive disorders
2. New series of anticonvulsant drugs tested by experiments on animals
3. The clinical use of carbamazepine in affective disorders
4. The medical and surgical management of trigeminal neuralgia
5. The treatment of trigeminal neuralgia (tic douloureux)
6. Carbamazepine prophylaxis in refractory affective disorders: a focus on longterm follow-up
7. Human liver carbamazepine metabolism
8. Comparative study of voltage-sensitive sodium channel blockers in focal ischaemia and electric convulsions in rodents
9. 3H]Batrachotoxinin A 20-gamma-benzoate to sodium channels by the anticonvulsant drugs diphenylhydantoin and carbamazepine
10. Antiepileptic drug actions
11. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture
12. On the mechanism of drug-induced blockade of Na+ currents: interaction of antiarrhythmic compounds with DPI-modified single cardiac Na+ channels
13. Modulated anticonvulsant block of sodium channels in nerve and muscle
14. Effect of diphenylhydantoin on electrolytes and on sodium turnover in brain and other tissues of normal, hypernatremic and postictal rats
15. Phenytoin: mechanisms of its anticonvulsant action
16. Mechanisms of action of currently prescribed and newly developed antiepileptic drugs
17. Neuropharmacology of antiepileptic medications: mechanisms of action
18. Phenytoin: biochemical membrane studies
19. Analysis of carbamazepine actions in hippocampal slices of the rat
20. Efficacy and safety of lamotrigine, a new anticonvulsant
21. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans
22. Anticonvulsant therapy, megaloblastic haemopoesis and folic acid metabolism
23. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action
24. Lamotrigine protects against kainate but not ibotenate lesions in rat striatum
25. The metabolism of 14C-oxcarbazepine in man
26. Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action
27. Oxcarbazepine: mechanisms of action
28. Oxcarbazepine and its monohydroxy metabolite limit action potential firing by mouse central neurons in cell culture
29. Prevention of Ca(2+)mediated action potentials in GABAergic local circuit neurones of rat thalamus by a transient K+ current
30. Specific petit mal anticonvulsants reduce calcium currents in thalamic neurons
31. Anticonvulsant activity and ethosuximide
32. Characterization of ethosuximide reduction oflow-threshold calcium current in thalamic neurons
33. Sodium valproate enhancement of gamma-aminobutyric acid (GAB A) inhibition: electrophysiological evidence for anticonvulsant activity
34. Familial intrauterine convulsions in pyridoxine dependency
35. Epilepsy and gamma-aminobutyric acid-mediated inhibition
36. GABA-agonists as anti-epileptic agents
37. Cellular mechanisms of epilepsy: a status report
38. Primidone, phenobarbital, and PEMA: II. Seizure protection, neurotoxicity, and therapeutic index of varying combinations in mice
39. Anticonvulsant drug mechanisms of action
40. Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital
41. Barbiturate reduction of calcium-dependent action potentials: correlation with anesthetic action
42. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds
43. Phenobarbital protects cerebral cortex neurones against toxicity induced by kainate but not by other excitatory amino acids
44. Benzodiazepine and beta-carboline interactions with GABAA receptor-gated chloride channels in mammalian cultured spinal cord neurons
45. Gabapentin as add-on therapy for refractory partial epilepsy: results of five placebo-controlled trials
46. Pharmacokinetics of gabapentin in subjects with various degrees of renal function
47. Gabapentin: a review of its pharmacological properties and clinical potential in epilepsy
48. Antiepileptic drugs in clinical development
49. Gabapentin actions on ligand- and voltage-gated responses in cultured rodent neurons
50. Antiepileptic drug mechanisms of action
51. Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin
52. Emerging perspectives on the mechanism of action of gabapentin
53. Vigabatrin
54. Pharmacokinetics of vigabatrin following single and multiple oral doses in normal volunteers
55. Potential antiepileptic drugs: vigabatrin
56. Gamma-vinyl GAB A (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T; effect on brain GABA metabolism in mice
57. Tiagabine
58. (R)-N-(4,4-bis(3-methyl-2-thienyl)but-3-en-l-yl)nipecotic acid (tiagabine) binds with high affinity to the brain GAB A uptake carrier
59. Clinical pharmacokinetics of valproic acid — 1988
60. Effect of stimulus intensity on the profile of anticonvulsant activity of phenytoin, ethosuximide and valproate
61. Comparison of the anticonvulsant activities of ethosuximide, valproate, and a new anticonvulsant, thiobutyrolactone
62. Sodium valproate decreases synaptic potentiation and epileptiform activity in hippocampus
63. Valproate-induced changes in GAB A metabolism at the subcellular level
64. Experimental studies and controlled clinical testing of valproate and vigabatrin
65. Valproic acid selectivity reduces the low-threshold (T) calcium current in rat nodose neurons
66. Felbamate: a new antiepileptic drug
67. Comparative anticonvulsant activity and neurotoxicity of fe1bamate and four prototype antiepileptic drugs in mice and rats
68. Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methylD-aspartate and gamma-aminobutyric acidA receptors
69. Advances in the assessment of refractory epilepsy